financetom
Business
financetom
/
Business
/
Hamilton Thorne's Q4 Profit Falls, Sales Rise; Provides 2024 Outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Hamilton Thorne's Q4 Profit Falls, Sales Rise; Provides 2024 Outlook
Mar 27, 2024 8:32 AM

11:01 AM EDT, 03/27/2024 (MT Newswires) -- Hamilton Thorne Ltd. ( HTLZF ) , a provider of precision instruments, laboratory equipment, consumables, software, and services to the Assisted Reproductive Technologies, research, and cell biology markets, was at last look on Wednesday up 1.5% after reporting fourth-quarter earnings of $540,237, or $0.00 per diluted share, down from $980,391, or $0.00 per diluted share, a year earlier.

Sales for the quarter ended Dec. 31, 2023, were $18.4 million, up from $16.4 million a year earlier. Adjusted EBITDA for Q4 was $3.7 million, up from $3 million a year earlier.

The company is expecting first-quarter revenue of $19 million to $19.4 million, with organic growth for the quarter of about 8%.

For the full 12 months of 2024, the company expects to deliver revenue of $78 to $82 million, reflecting 10% to 15% organic growth for the full year.

"In 2023, we made significant investments in our operations to facilitate long-term growth. Management is committed to EBITDA margin expansion and we anticipate tighter operating expense control in 2024, while continue to leverage our larger scale. We anticipate Q1 of 2024 to be our lowest EBITDA margin quarter in 2024 at approximately 18%, but in the range of 19.5% to 20.5% for the full year. Cash flow is expected to improve as the investment in expanding capacity has been completed and inventory will decrease in the following months," Francesco Fragasso, the company's chief financial officer, said.

Price: 1.32, Change: +0.02, Percent Change: +1.54

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2025 - www.financetom.com All Rights Reserved